Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

52.53EUR
17 Jun 2019
Change (% chg)

€-0.32 (-0.61%)
Prev Close
€52.85
Open
€52.79
Day's High
€52.98
Day's Low
€52.21
Volume
2,295,087
Avg. Vol
3,489,438
52-wk High
€99.90
52-wk Low
€52.02

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €96,918.28
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.30

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 22.18 29.30 32.55
EPS (TTM): 5.29 -- --
ROI: 8.69 14.23 13.82
ROE: 16.39 15.46 15.24

Bayer to invest $5.6 billion in weedkiller research to help reputation

FRANKFURT Germany's Bayer sought to repair its reputation on Friday after damage caused by U.S. litigation over claims its glyphosate pesticide causes cancer, saying it would invest 5 billion euros ($5.6 billion) in weedkiller research.

14 Jun 2019

UPDATE 2-Bayer to invest $5.6 bln in weedkiller research to help reputation

* CEO seeks to improve image amid U.S. glyphosate lawsuits (Adds details on investment, developing countries, lobbyist)

14 Jun 2019

Bayer says to invest five billion euros in new weed killers

BERLIN Bayer said it would invest 5 billion euros (£4.5 billion) in developing new weedkillers and reducing its environmental impact by 30% by 2030, as it seeks to address the fallout from U.S. class-action litigation over glyphosate.

14 Jun 2019

Bayer says to invest 5 bln euros in new weed killers

BERLIN, June 14 Bayer said it would invest 5 billion euros ($5.6 billion) in developing new weedkillers and reducing its environmental impact by 30% by 2030, as it seeks to address the fallout from U.S. class-action litigation over glyphosate.

14 Jun 2019

Bayer teams up with biotech firm Arvinas in deal worth up to $750 million

FRANKFURT German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.

04 Jun 2019

Bayer teams up with biotech firm Arvinas in deal worth up to $750 mln

FRANKFURT, June 4 German drugmaker Bayer has signed an alliance with Arvinas Inc to gain access to the U.S. biotech firm's experimental protein drugs and crop protection technology in a deal worth up to $750 million.

04 Jun 2019

Australian gardener sues Bayer's Monsanto over cancer link

SYDNEY Lawyers of an Australian gardener on Tuesday said they had filed a lawsuit against Bayer AG agricultural chemicals unit Monsanto for severe harm caused by an ingredient used in its weed killer Roundup, the first such case in the country.

04 Jun 2019

Australian gardener sues Bayer's Monsanto over cancer link

SYDNEY, June 4 Lawyers of an Australian gardener on Tuesday said they had filed a lawsuit against Bayer AG agricultural chemicals unit Monsanto for severe harm caused by an ingredient used in its weed killer Roundup, the first such case in the country.

04 Jun 2019

Bayer to work with Foundation Medicine on cancer patient screening

FRANKFURT Bayer announced a collaboration deal with Roche's Foundation Medicine Inc. to develop a test for sequencing tumour genomes to identify patients who can benefit from Bayer's cancer drug hopeful Vitrakvi.

29 May 2019

UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening

* Genetic sequencing test seen as vital to secure market uptake

29 May 2019

Earnings vs. Estimates